AICentralResources
AI Tool Comparison

Comparing as AI Medical Research & Clinical Decision Support
Paige vs Nabla

Paige

Paige

VS
Nabla

Nabla

Verdict by Category

Detailed category analysis is not available for this comparison.
View Paige View Nabla

Detailed Comparison

Feature
Paige
Nabla
Pricing
EnterprisePaige operates exclusively on enterprise contracts with hospital pathology departments, cancer centers, and biopharma companies. There is no published pricing or self-serve option. Clinical deployments are priced based on institution size, scanner ecosystem, patient volume, and AI modules deployed (FullFocus, Paige Prostate, Paige Breast, etc.). Biopharma partnerships are structured as research service agreements for biomarker discovery, companion diagnostic development, and drug trial tissue analysis. Contact Paige through paige.ai to arrange an enterprise discovery call and platform demonstration.
FreemiumNabla does not publish exact pricing on its official website; the primary calls-to-action are a free trial (via app.nabla.com) and "Talk to our team" for enterprise sales. Third-party sources consistently report a free tier with usage limits, with paid individual/clinician plans starting around $119/month per provider and higher tiers reported near $239/month per provider. Larger health-system deployments — Nabla's core market, spanning 130+ organizations — are sold via custom enterprise contracts with volume-based pricing, with independent estimates placing typical enterprise rates in the $150-$400/month per provider range depending on scale, EHR integration depth, and features. Exact costs require a sales conversation with Nabla.
Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Productivity ToolsAI Developer APIs & Platforms
Summary
Computational pathology AI from MSK — the first FDA-cleared platform for AI-assisted cancer diagnosis
Ambient AI that turns patient visits into clinical notes, dictation, and coding — right inside the EHR
Paige

Paige Pros & Cons

Pros

  • First FDA clearance for AI in primary pathology diagnosis — a historic regulatory milestone
  • First CE mark for AI pathology in Europe — validated for clinical use across EU
  • Founded on MSK's 25M+ pathology slides — the richest cancer pathology training set in the world
  • AIRI infrastructure with 10+ petaFLOPS — enterprise-grade AI compute at clinical scale
  • FullFocus viewer is scanner-neutral with FDA clearances for Leica, Hamamatsu, and Philips
  • The most credentialed AI pathology company in terms of regulatory approvals
  • Backed by Goldman Sachs, Breyer Capital, and Healthcare Venture Partners

Cons

  • Enterprise and institutional access only — not available to small or independent pathology labs
  • No published pricing — all contracts negotiated through enterprise procurement
  • Requires digital pathology infrastructure — scanners, storage, and LIS integration
  • Pathologist review and sign-off still required for all AI-generated results
  • Focused on pathology and oncology — not a general medical imaging platform
Nabla

Nabla Pros & Cons

Pros

  • Fast note generation, roughly five seconds, that closely mirrors real clinical documentation in independent tests
  • Deep native integration with Epic and other major EHRs rather than copy-paste workflows
  • Broad specialty and language coverage suited to large, diverse health systems
  • Strong compliance posture (HIPAA, SOC 2 Type 2, ISO 27001, GDPR) with configurable data retention
  • Backed by peer-reviewed evidence, including a NEJM AI randomized trial showing documentation-time reductions
  • Combines documentation, dictation, and coding in one platform instead of separate point tools

Cons

  • Pricing isn't published; individuals and smaller practices must go through a sales conversation or rely on third-party estimates to budget
  • Primarily built for hospitals and health systems, so solo clinicians and small practices may find it less tailored than SMB-focused scribes
  • Relies on ambient recording, so encounters where a patient or clinician can't or won't be recorded aren't well supported
  • Some independent reviews note limited customization and quality drop-off on complex, multi-problem visits
  • Mobile app store ratings are mixed and based on a relatively small number of reviews compared to the platform's overall clinician base